A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma. Blood cancer journal Ramasamy, K., Nooka, A., Quach, H., Htut, M., Popat, R., Liedtke, M., Tuchman, S. A., Laubach, J., Gasparetto, C., Chanan-Khan, A., Hertzberg, M., deMario, M., Nueesch, E., Chesne, E., Franjkovic, I., Lechner, K., Kornacker, M., Cho, H. J. 2021; 11 (9): 149

View details for DOI 10.1038/s41408-021-00545-w

View details for PubMedID 34480019